Vivani Medical, Inc. - Common Stock VANI 深 沪
等待开盘 10-07 09:30:00 美东时间
1.41
+0.010
+0.71%
华盛通- 最 高1.475
- 今 开1.41
- 成交量 15.43万股
- 最 低 1.41
- 昨 收 1.40
- 总市值 8353.39万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 0.9054
- 委 比 96.02%
- 总股本 5924.39万
- 历史最高 576.48
- 量 比 1.27
- 振 幅 4.64%
- 历史最低 0.7536
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Advani Hotels & Resorts Addresses AGM Proceedings Delay
Advani Hotels & Resorts (India) Ltd. ( ($IN:ADVANIHOTR) ) has shared an upd...
10-04 16:12
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
Vivani Medical, Inc. will present at the Emerging Growth Conference 86 on September 25, 2025, at 1:45 pm ET. CEO Adam Mendelsohn will discuss the Company's miniature, ultra-long-acting drug implants for metabolic diseases and respond to pre-submitted questions. The presentation will be available via webcast, with an archived version accessible post-conference. For more details, visit the provided links or contact the company directly. (258 chara...
09-24 13:15
H.C. Wainwright Reaffirms Their Buy Rating on Vivani Medical (VANI)
In a report released yesterday, Yi Chen from H.C. Wainwright reiterated a Buy r...
09-18 16:15
Vivani Sets October 8 Record Date For Spin-Off Of Cortigent, To Trade Under Nasdaq Ticker 'CRGT'
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind
09-17 20:35
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
Vivani Medical announced the planned spin-off of its subsidiary Cortigent, a leader in brain implant technology, to create a separate publicly traded company. Cortigent specializes in precision neurostimulation devices, having developed the only FDA-approved system for artificial vision for the profoundly blind. The company's Orion artificial vision system has completed a successful 6-year Early Feasibility Study and is now preparing for pivotal ...
09-17 12:30
Vivani Medical Shares Insights at Industry Conferences
Vivani Medical ( ($VANI) ) has provided an update. Vivani Medical, Inc. regular...
09-10 04:51
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
Vivani Medical plans to initiate a Phase 1 clinical study for its NPM-139 semaglutide implant program in the first half of 2026, pending regulatory clearance. The product aims to provide Wegovy-level efficacy with once or twice-yearly administration for chronic weight management in obese or overweight patients. The Phase 1 study will assess safety, tolerability, and pharmacokinetics, while the Phase 2 study will evaluate efficacy and determine th...
09-04 12:30
HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
09-02 19:07
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present and host partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, in New York. Mendelsohn will discuss Vivani's miniature, ultra-long-acting drug implants, including the advancement of NPM-139, a semaglutide implant for chronic weight management. The presentation will highlight the Company's NanoPortal™ technology, aimed at impro...
08-20 12:30
Vivani Medical Secures $10M Through Share Purchase Agreement
Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Med...
08-14 05:17
